PEPTIDE PERSPECTIVES™

PEPTIDES • LONGEVITY • PERFORMANCE • HEALTH OPTIMIZATION

THE MEN'S HORMONAL HEALTH STACK

Peptides, Supplements for Testosterone, Vitality & Healthy Aging

THE BIG PICTURE: VITALITY IS NOT ONE HORMONE

- **Vitality is multi-factorial.** Testosterone, fertility, sexual function, energy, body composition, and overall well-being are related, but different outcomes.
- **Peptides can affect different endocrine pathways** (e.g., HPG axis and GH axis), which may influence hormones and downstream effects.
- **Stacking does not automatically create synergy.** Combining peptides may not produce additive or superior results, and can also increase complexity and risk.

- **Testosterone** (hormone level)
- **Fertility** (sperm production)
- **Sexual Function** (libido, performance)
- **Energy** (vitality, drive)
- **Body Composition** (lean mass, fat mass)
- **Well-Being** (mood, motivation, QOL)



TWO KEY HORMONE AXES: HPG vs. GH

HPG AXIS
(Reproductive / Testosterone Axis)



Hypothalamus
↓
GnRH (Gonadotropin-Releasing Hormone)
↓
Pituitary (Anterior)
↓
LH (Luteinizing Hormone) | FSH (Follicle-Stimulating Hormone)
↓
Testes (Leydig & Sertoli cells)
↓
Testosterone + Spermatogenesis (sperm production)

GH AXIS
(Growth Hormone / IGF-1 Axis)



Hypothalamus / Pituitary
↓
GH (Growth Hormone) ← CJC-1295 (GHRH analog) + Ipamorelin (Ghrelin-receptor agonist)
↓
IGF-1 (Insulin-Like Growth Factor-1)

ⓘ **GH / IGF-1 is not the same as testosterones.** It's a separate hormone axis with different primary effects (e.g., growth, recovery, and body composition).

KEY PATHWAYS: HOW THEY WORK & WHY IT MATTERS

HPG SIGNALING / REPRODUCTIVE HORMONES

The hypothalamic–pituitary–gonadal (HPG) axis regulates LH and FSH, which control testicular function, testosterone production, and sperm production.

TESTICULAR LH RECEPTOR STIMULATION

hCG can directly activate LH receptors on Leydig cells in the testes, which can increase intratesticular testosterone and support overall testosterone production.

SPERMATOGENESIS / FERTILITY SUPPORT

FSH (and supportive protocols) acts on Sertoli cells to support spermatogenesis (sperm production), which is essential for male fertility and reproductive health.

GH / IGF-1 AND BODY-COMPOSITION SIGNALING

GH (often targeted with CJC-1295 and ipamorelin) increases GH pulses, which can raise IGF-1. This axis is primarily linked to growth, recovery, and body composition (e.g., lean mass and fat mass), not to direct testosterone production.

MEN'S HORMONAL HEALTH STACKS: COMMUNITY PROTOCOLS (NOT VALIDATED)

STACK 1

COMMUNITY-REPORTED

hCG + Kisspeptin



hCG + Kisspeptin

- **Logic:** Downstream LH-receptor stimulation (hCG) plus upstream GnRH signaling (kisspeptin).
- **hCG (community-reported):** 250–500 IU subcutaneous 2–3×/week.
- **Kisspeptin-10 (community-reported):** 100–300 mcg subcutaneous 2–3×/week.

ⓘ **Anecdotal:** no validated long-term stack protocol.

STACK 2

SPECIALIST-ONLY / DIAGNOSIS-DEPENDENT

hCG + GnRH-Related Therapy



hCG + GnRH

- **Logic:** Specialist-directed restoration of pituitary signaling (GnRH) plus testicular support (hCG).
- **hCG (clinical/community context):** 500–1,500 IU subcutaneous 2–3×/week.
- **GnRH-related therapy:** Specialist protocol only; pulsatile delivery, no standard community home protocol.

⚠ **Diagnosis-dependent:** not a general healthy-aging stack.

STACK 3

COMMUNITY-REPORTED (GH-AXIS)

CJC-1295 + Ipamorelin



CJC-1295 + Ipamorelin

- **Logic:** Combine GHRH signaling (CJC-1295) with ghrelin-receptor signaling (Ipamorelin) to raise GH pulses.
- **CJC-1295 (community-reported):**
  - **No DAC:** 100–200 mcg 1–2×/day OR
  - **DAC:** 1–2 mg weekly.
- **Ipamorelin (community-reported):** 100–300 mcg 1–2×/day.

ⓘ **Anecdotal / research-oriented:** GH-axis stack, not a proven testosterone stack.

STACK 4

SPECULATIVE (COMMUNITY-REPORTED)

Kisspeptin + CJC-1295



Kisspeptin + CJC-1295

- **Logic:** HPG axis (kisspeptin) + GH axis (CJC-1295) in parallel.
- **Kisspeptin-10 (community-reported):** 100–300 mcg subcutaneous 2–3×/week.
- **CJC-1295 (community-reported):**
  - **No DAC:** 100–200 mcg 1–2×/day OR
  - **DAC:** 1–2 mg weekly.

ⓘ **Highly speculative:** no controlled combination outcome data.

STACK 5

CLINICAL COMPARATOR (FERTILITY CONTEXT)

hCG + FSH
(Clinical Fertility Comparator)



hCG + FSH

- **Logic:** Testosterone support (hCG) plus Sertoli-cell / sperm-production signaling (FSH).
- **hCG (clinical fertility context):** 1,500–2,000 IU subcutaneous 2–3×/week.
- **FSH (clinical context):** 75–150 IU subcutaneous 2–3×/week.

ⓘ **Clinical comparator:** specialist-managed fertility protocol, not a casual vitality stack.

STACK 6

COMMUNITY CONTEXT (NOT A PEPTIDE STACK)

hCG + SERM or AI Adjunct



hCG + SERM or AI

- **Logic:** Used by some community users to manage endocrine feedback (e.g., maintain endogenous signaling) or estradiol balance.
- **hCG (community-reported):** 250–500 IU subcutaneous 2–3×/week.
- **SERM (community context):** Enclomiphene or clomiphene often 12.5–25 mg/day or several times weekly.
- **AI (community context):** Anastrozole often 0.25–0.5 mg 1–2×/week.

ⓘ **Anecdotal community context:** not a peptide stack; use with caution.

SUPPORTIVE SUPPLEMENTS & LIFESTYLE FOUNDATIONS

Zinc	15–30 mg/day
Vitamin D3	1,000–4,000 IU/day (depending on deficiency / labs)
Magnesium	200–400 mg/day
Creatine (monohydrate)	3–5 g/day
Ashwagandha	300–600 mg/day
Boron	3–6 mg/day
Omega-3s	1–2 g/day EPA + DHA
Protein / Energy Sufficiency	Adequate protein and total caloric intake support recovery, muscle, and overall hormone health.

KEY LIFESTYLE FOUNDATIONS

- **Sleep** (quality & duration)
- **Resistance Training** (muscle, metabolic & hormonal health)
- **Visceral-Fat Reduction** (especially abdominal fat)
- **Treat Sleep Apnea** (if present, optimize treatment)

EVIDENCE & KEY TAKEAWAYS



- Stronger evidence exists for **diagnosis-based endocrine care** (e.g., hypogonadism, fertility) than for community peptide stacks.
- **hCG and hCG + FSH** have legitimate fertility / hypogonadotropic uses in selected patients (e.g., to stimulate testosterone and sperm production).
- **Kisspeptin** is early human research with promising endocrine effects, but it is not yet an established, validated therapy for routine use.
- **CJC-1295 + Ipamorelin** is mainly a GH-axis research concept (increasing GH and IGF-1), with potential effects on recovery and body composition.
- **More GH does not equal more testosterone.** The GH / IGF-1 axis and the HPG (testosterone) axis are different systems with different primary roles.

MONITORING & SAFETY



- Confirm low testosterone with two separate early-morning labs (e.g., total testosterone).
- Consider LH, FSH, estradiol (E2), SHBG, prolactin, and free testosterone (e.g., calculated or direct).
- Semen analysis matters when fertility is the goal (e.g., sperm count, motility, and morphology).
- hCG may increase estradiol and fluid retention (e.g., via increased aromatization).
- GH-axis peptides (e.g., CJC-1295, ipamorelin) may cause edema (fluid retention), joint symptoms (e.g., aches), and potential glucose issues (e.g., increased insulin resistance).
- Peptide products may have purity, sterility, and immunogenicity concerns (e.g., contaminants, incorrect dosing, or immune reactions).
- Compounded CJC-1295, ipamorelin, and kisspeptin-10 have FDA safety-information gaps (not FDA-approved for these uses). Use only with appropriate medical oversight and awareness of risk.

⚠ COMMUNITY PROTOCOLS ARE ANECDOTAL, NOT VALIDATED TREATMENT PLANS.

TESTOSTERONE, FERTILITY, LIBIDO, STRENGTH & WELL-BEING ARE DIFFERENT OUTCOMES.

Educational research overview | November 2026 | Not medical advice